

---

## ENTRY INTO LOAN AGREEMENT FOR THE HOSPITAL PROJECT IN PRINCE BAY, SHENZHEN

---

1. The Board of Directors (the "**Board**") of OUE Lippo Healthcare Limited (the "**Company**") wishes to announce that Le Kang Assets (Shenzhen) Co. Ltd. (乐康置业(深圳)有限公司) (the "**Project Company**"), an associated company of the Company, has entered into a loan agreement (the "**Loan Agreement**") with Bank of China Limited (the "**Lender**") for the grant of a loan of RMB 330 million (approximately SGD 70 million<sup>1</sup>) (the "**Loan**") to the Project Company. The tenure of the Loan is 15 years, subject to the terms and conditions of the Loan Agreement. The Loan Agreement will be effective from the date of this announcement.
2. The Project Company is wholly owned by Riviera Quad International Limited (乐活置业国际有限公司) ("**Riviera Quad**"), which is indirectly owned in equal proportion by the Company and the Company's independent third-party joint venture partner, China Merchants Shekou Industrial Zone Holdings Co., Ltd. (招商局蛇口工业区控股股份有限公司) ("**CMSK**").
3. The Loan will be used by the Project Company for the construction and renovation of the Prince Bay Hospital, a high-end international hospital in Prince Bay, Shekou, Shenzhen, the People's Republic of China (the "**Prince Bay Hospital**").
4. The Loan is secured by:
  - (a) a pledge of 100% of the total issued shares in the Project Company held by Riviera Quad;
  - (b) a mortgage over the Project Company's land and construction work in progress in respect of the Prince Bay Hospital;
  - (c) corporate guarantees by each of the Company (the "**Company Guarantee**") and CMSK for 50% of the Loan respectively, in proportion to their effective shareholding in the Project Company; and
  - (d) when the Prince Bay Hospital commences operations, security over the operational bank account maintained with the Lender and rent collected by the Project Company.
5. Neither the entry into the Loan Agreement by the Project Company nor the entry into the Company Guarantee by the Company is expected to have any material impact on the earnings per share or the net tangible assets of the Company for the financial year ending 31 December 2022.
6. None of the Directors of the Company has any interest, direct or indirect, in the transactions contemplated herein.
7. The Company will make further announcements, in compliance with the requirements of the Catalist Rules, as and when there are material developments in respect of the transactions and/or other matters contemplated by this announcement. Shareholders and potential investors of the Company should exercise caution when trading in the shares of the Company. In the event of any doubt as to the action they should take, shareholders should consult their financial, tax, legal or other professional advisers.

---

<sup>1</sup> Based on the exchange rate of SGD 1 : RMB 4.6970.

### **OUE Lippo Healthcare Limited**

Company Registration No. 201304341E

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 Web: www.ouelh.com

By Order of the Board

**OUE Lippo Healthcare Limited**

Mr. Yet Kum Meng  
Chief Executive Officer and Executive Director  
28 March 2022

---

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

*The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.*